To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

NCT07364422 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer (GC)

Interventions

DRUG: JPI-547
DRUG: Irinotecan (drug)

Sponsor

Onconic Therapeutics Inc.